Phase 2
Completed N=20
A Study of Ultra High Dose Diuretics to Treat Heart Failure
Heart Failure; With Decompensation
Source: ClinicalTrials.gov NCT06036914 ↗
Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcomePrimary: Urine Output — 5283; 2819 mL
Summary
The purpose of this study is to determine the safety and effectiveness of ultrahigh dose diuretics compared to standard dose diuretics over 24 hours in patients with decompensated heart failure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Urine Output |
5283; 2819 | — |
| SECONDARY Change in Body Weight |
-2.6; -3.8 | — |
| SECONDARY Change in NT-proBNP |
2898; -1705 | — |
| SECONDARY Change in Urine Sodium Excretion |
— | — |
| SECONDARY Change in Apnea-hypopnea Index |
— | — |
| SECONDARY Change in Iohexol Glomerular Filtration Rate (GFR) |
— | — |
| SECONDARY Change in Peripheral Vein Pressure |
-10.9; -4 | — |
| SECONDARY Change in Cardiac Output |
-0.53; 0.29 | — |
| SECONDARY Change in Estimated Right Ventricular (RV) Systolic Pressure |
— | — |
| SECONDARY Change in Right Atrial (RA) Pressure |
— | — |
| SECONDARY Change in Left Atrial (LA) Strain |
— | — |
| SECONDARY Change in Left Ventricular (LV) Global Longitudinal Strain |
— | — |
| SECONDARY Change in Right Ventricular (RV) Global Longitudinal Strain |
— | — |
| SECONDARY Change in E/e' |
— | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of decompensated heart failure receiving intravenous diuretics
- Ability to provide informed consent
Exclusion Criteria
- Patients on home inotrope medications
- Patients with Chronic Kidney disease stage V and end stage renal failure on dialysis
- Patients lacking the capacity to consent for themselves
- Known pregnancy or breastfeeding mothers
- Complex congenital heart disease
- Allergy to furosemide or bumetanide
- Respiratory failure requiring non-invasive ventilation (CPAP/BiPAP) or invasive mechanical ventilatory support at the time of randomization
- Hypotension with systolic blood pressure <80 mm Hg at the time of randomization
- Acute coronary syndrome
- Sustained Ventricular tachycardia requiring treatment in the last 48 hours
- Patients weighing ≤ 40 kg
Data sourced from ClinicalTrials.gov (NCT06036914). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.